SYS-CON MEDIA Authors: Cynthia Dunlop, Scott Bampton, Greg Ness, Elizabeth White, Glenn Rossman

News Feed Item

As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Manufacturer's Threat of Legal Action Against Uterine Morcellation Critic

NEW YORK, Aug. 29, 2014 /PRNewswire/ -- As power morcellator lawsuit (http://www.gynecaremorcellatorlawsuit.com/) filings continue to mount in U.S. courts, Bernstein Liebhard LLP notes that one medical device manufacturer is taking issue with a doctor who is working to have uterine morcellation banned in the U.S. According to a report from The Cancer Letter, the Karl Storz Group has sent a letter to Dr. Hooman Noorchashm threatening him with legal action if he does not end his campaign against the Rotocut morcellator, a device manufactured by the company. For his part, Dr. Noorchashm says he has no intention of ending his crusade.*

Bernstein Liebhard LLP.

"This letter is a strong indication that Dr. Noorchashm's work is having an impact. It's doubtful that this issue would have gained any traction had he and his wife not brought it to the attention of health regulators and the public," says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now offering hysterectomy cancer lawsuit reviews to women who suffered uterine sarcoma or other cancers allegedly spread by morcellation.

Uterine Morcellation and Cancer

Power morcellators are used in minimally-invasive uterine surgeries to cut up tissue so that it can be removed via a small abdominal incision. According to The Cancer Letter report, Dr. Noorchashm began working for a power morcellator ban last fall, after his wife, Dr. Amy Reed, was diagnosed with Stage 4 uterine cancer shortly after she underwent a hysterectomy to remove fibroids. He claims that the Rotocut morcellator was used in his wife's surgery, and has urged Karl Storz to recall the device. Dr. Noorchashm has also launched a Change.org petition to ban uterine morcellation that has so far collected more than 75,000 signatures.**

On April 17, 2014, a U.S. Food & Drug Administration (FDA) alert discouraged doctors from using the devices in laparoscopic hysterectomy and fibroid removals, because of the risk that they could promote the spread of undetected uterine sarcomas and other cancers. These cancers are difficult to detect prior to surgery, and their dissemination during uterine morcellation can quickly upstage the cancer and significantly reduce a woman's chances for long-term survival, the FDA said.

In July, the FDA convened a meeting of outside advisors to discuss the procedure's risks and benefits. During the meeting, Drs. Noorchashm and Reed, as well as many others, urged the agency to ban the use of power morcellators in uterine surgery.

Shortly after the FDA's July meeting, a power morcellator recall was announced by Johnson & Johnson for three devices manufactured by Ethicon, Inc. unit. The company said it had decided to recall the morcellators because of the uncertainty surrounding their safety.

According to court documents, a number of power morcellator manufacturers are now facing lawsuits that allege their devices caused the dissemination of uterine cancer cells in patients undergoing laparoscopic hysterectomies and fibroid removal surgeries. Most recently, a morcellator lawsuit was filed against Karl Storz in the U.S. District Court, Eastern District of New York by a woman who claims the company's Rotocut G1 morcellator spread leiomyosarcoma, an aggressive form of uterine sarcoma, throughout her body. The August 18th filing alleges that the company failed to warn doctors and patients about the risks associated with the device. (Case No. 3:14-cv-01024-TJM-DEP)

Women whose uterine cancers were allegedly spread via a power morcellator may be entitled to compensation for medical bills, lost wages, pain and suffering, and other injury related damages. To learn more about the risks potentially associated with uterine morcellation, please visit Bernstein Liebhard LLP's website. To obtain a free legal review, please call (888) 340-4807.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(888) 340-4807

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Logo - http://photos.prnewswire.com/prnh/20120202/MM47134LOGO

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.gynecaremorcellatorlawsuit.com/
https://plus.google.com/115936073311125306742?rel=author 

SOURCE Bernstein Liebhard LLP

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The major cloud platforms defy a simple, side-by-side analysis. Each of the major IaaS public-cloud platforms offers their own unique strengths and functionality. Options for on-site private cloud are diverse as well, and must be designed and deployed while taking existing legacy architecture and infrastructure into account. Then the reality is that most enterprises are embarking on a hybrid cloud...
Samsung VP Jacopo Lenzi, who headed the company's recent SmartThings acquisition under the auspices of Samsung's Open Innovaction Center (OIC), answered a few questions we had about the deal. This interview was in conjunction with our interview with SmartThings CEO Alex Hawkinson. IoT Journal: SmartThings was developed in an open, standards-agnostic platform, and will now be part of Samsung's Ope...
Dyn solutions are at the core of Internet Performance. Through traffic management, message management and performance assurance, Dyn is connecting people through the Internet and ensuring information gets where it needs to go, faster and more reliably than ever before. Founded in 2001 at WPI, Dyn’s global presence services more than four million enterprise, small business and personal customers.
SYS-CON Events announced today that TeleStax, the main sponsor of Mobicents, will exhibit at Internet of @ThingsExpo, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. TeleStax provides Open Source Communications software and services that facilitate the shift from legacy SS7 based IN networks to IP based LTE and IMS networks hosted on private (...
The Internet of Things will greatly expand the opportunities for data collection and new business models driven off of that data. In her session at Internet of @ThingsExpo, Esmeralda Swartz, CMO of MetraTech, will discuss how for this to be effective you not only need to have infrastructure and operational models capable of utilizing this new phenomenon, but increasingly service providers will nee...
Things are being built upon cloud foundations to transform organizations. This CEO Power Panel at 15th Cloud Expo, moderated by Roger Strukhoff, Cloud Expo and @ThingsExpo conference chair, will address the big issues involving these technologies and, more important, the results they will achieve. How important are public, private, and hybrid cloud to the enterprise? How does one define Big Data? ...
European data center operator DEAC is the largest in the Baltics. The activities are orientated to provide data center services and IT outsourcing on Eurasia and America scale in order to create the primary or backup or additional data center for customer in the EU, to protect its business and, most importantly, reduce costs up to 40% within 3-5 years. DEAC is an IT outsourcing services and sol...
Until recently, many organizations required specialized departments to perform mapping and geospatial analysis, and they used Esri on-premise solutions for that work. In his session at 15th Cloud Expo, Dave Peters, author of the Esri Press book Building a GIS, System Architecture Design Strategies for Managers, will discuss how Esri has successfully included the cloud as a fully integrated SaaS ...
The 4th International DevOps Summit, co-located with16th International Cloud Expo – being held June 9-11, 2015, at the Javits Center in New York City, NY – announces that its Call for Papers is now open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and ...
We live in a time when seconds – even milliseconds – can have a dramatic economic impact on your company’s future. With technology being the primary conduit for consumer interaction, the user experience is at center stage. User experience will be a deciding factor in separating the future winners from the losers. By building more speed and agility into the application delivery process, DevOps prom...